UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 10, 2022
IRADIMED CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-36534
73-1408526
(Commission File Number)
(IRS Employer Identification No.)
1025 Willa Springs, Dr., Winter Springs FL 32708            
    (Address of Principal Executive Offices)
(Zip Code)         

(407) 677-8022
(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class:
  
Trading Symbol
  
Name of each exchange on which registered:
Common stock, par value $0.0001
  
IRMD
  
NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □


Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Iradimed Corporation (“Iradimed”) was held on Friday, June 10, 2022. At the meeting, Iradimed’s stockholders voted on the following four proposals and cast their votes as described below.

1.
Stockholders elected each of Roger Susi, Monty Allen, Anthony Vuoto and James Hawkins to Iradimed’s Board of Directors, each to hold office until a succeeding annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified (or, if earlier, such director’s removal or resignation from our Board), as set forth below.

Name
Votes For
Votes Withheld
Broker Non-Votes
Roger Susi
8,461,283
1,931,789
996,951
Monty Allen
7,480,354
2,912,718
996,951
Anthony Vuoto
8,066,334
2,326,738
996,951
James Hawkins
8,066,548
2,326,524
996,951

2.
Stockholders ratified the selection of RSM US LLP as Iradimed’s independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2022, as set forth below.

Votes For
Votes Against
Abstentions
11,379,731
9,204
1,088

3.
Stockholders approved an advisory resolution on the compensation of Iradimed’s named executive officers.

Votes For
Votes Against
Abstentions
Broker Non-Votes
10,235,323
139,607
18,142
996,951

4.
Stockholders voted, on an advisory basis, on the frequency of future advisory votes on executive compensation.

1 Year
2 Years
3 Years
Abstentions
10,287,164
6,812
96,160
2,936


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 IRADIMED CORPORATION
 
 
   
Date: June 10, 2022 By:
 /s/Matt Garner
  Name:
 Matt Garner
  Title:
 Controller – Interim CFO